SCHEMBL675097

SCHEMBL675097

CCCCC(N)c1ccc2c(n1)[nH]c1ccc(/C=C/c3ccccc3)cc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IP6K1 Q92551 3/20 0.37
MAPKAPK2 P49137 2/20 0.35
KDM4E B2RXH2 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
TSHR P16473 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ALK Q9UM73 4/20 0.33
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
CA5A P35218 1/20 0.32
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31
BRD4 O60885 1/20 0.31
IP6K3 Q96PC2 1/20 0.31
IP6K2 Q9UHH9 1/20 0.31
GABRP O00591 1/20 0.31
GABRD O14764 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL675668 0.89 TAS1R3 (0.37) KDM4ECYP1A2ALKMAPTSMN1; SMN2
SCHEMBL676200 0.84 GSK3B (0.37) KDM4ECYP1A2CYP3A4TSHRHSD17B10
SCHEMBL676561 0.80 IP6K1 (0.36) IP6K1MAPKAPK2KDM4ECYP1A2CYP3A4
SCHEMBL675100 0.79 IP6K1 (0.37) IP6K1MAPKAPK2KDM4ECYP1A2CYP3A4
SCHEMBL676274 0.78 ALK (0.44) IP6K1MAPKAPK2KDM4ECYP3A4ALK
SCHEMBL3725585 0.78 GABRP (0.40) IP6K1MAPKAPK2KDM4ECYP1A2CYP3A4
SCHEMBL3725587 0.78 GABRP (0.40) IP6K1MAPKAPK2KDM4ECYP1A2CYP3A4
SCHEMBL676277 0.77 IP6K1 (0.37) IP6K1MAPKAPK2ALKTP53MAPT
SCHEMBL676564 0.77 IP6K1 (0.37) IP6K1MAPKAPK2CYP1A2ALKCA5A
SCHEMBL676306 0.77 MAPKAPK2 (0.38) IP6K1MAPKAPK2KDM4ECYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895744-B2 Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) 2014-11-25 US disclosed
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2011-11-17 US disclosed
EP-2161271-A1 Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl Università Degli Studi Di Milano - Bicocca (IT) 2010-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL ALK, BCR, NPM1 IP6K1 3330/4885MAPKAPK2 2823/4885KDM4E 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.